Reuters logo
BRIEF-Protalix Biotherapeutics enters into partnership with Chiesi Farmaceutici
2017年10月18日 / 下午1点00分 / 1 个月前

BRIEF-Protalix Biotherapeutics enters into partnership with Chiesi Farmaceutici

Oct 18 (Reuters) - Protalix Biotherapeutics Inc:

* Protalix Biotherapeutics enters into an exclusive ex-US partnership with Chiesi Farmaceutici for the development and commercialization of PRX-102 (pegunigalsidase alfa) for the treatment of fabry disease

* Protalix - co grants chiesi ex-US rights to PRX-102, a chemically modified version of recombinant protein alpha-galactosidase-a protein​

* Protalix Biotherapeutics Inc - ‍to receive $25 million upfront, an additional up to $25 million in development costs​

* Protalix Biotherapeutics Inc - ‍Protalix to receive tiered royalties ranging from 15% to 35% on net sales as part of deal​

* Protalix Biotherapeutics Inc - ‍to receive an additional up to $320 million in potential regulatory and commercial milestone payments​

* Protalix Biotherapeutics - ‍under terms of agreement, Protalix has licensed prx-102 to chiesi for all markets outside of United States​

* Protalix Biotherapeutics - co will continue to be manufacturer of PRX-102 for clinical development purposes & commercial purposes after marketing approvals​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below